Liquidia Corporation (LQDA) — Stock Score Summary

Liquidia Corporation (LQDA) has a MoatMap StockRank of 69/100 based on Quality (63/100), Value (8/100), and Momentum (81/100) factor scores. The current signal is BUY. Liquidia is a biopharmaceutical company with significant regulatory and litigation risks surrounding its pulmonary arterial hypertension treatments. This binary risk profile and lack of established cash flows fail the Buffett margin of safety and Terry Smith quality criteria.

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing innovative therapies using its proprietary PRINT® technology, which precisely controls particle size and shape for drug delivery. This advanced technology provides a significant competitive edge by enabling improved drug efficacy and patient outcomes for conditions like pulmonary arterial hypertension. Liquidia is a niche player aiming to disrupt existing treatment paradigms with novel formulations.

Key Financial Metrics

Price$55.69
Market Cap$5.5B
P/E (TTM)367.88
P/E (Forward)11.22
Price/Book50.85
Return on Equity28.2%
Return on Invested Capital-23.3%
Debt/Equity170.22
Gross Margin91.8%
Operating Margin46.3%
Revenue Growth4158.5%
Free Cash Flow$10M

Liquidia Corporation operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Liquidia Corporation’s (LQDA) StockRank?
MoatMap’s StockRank for Liquidia Corporation (LQDA) is 69/100, with a Buy signal. It is a composite of Quality (63), Value (8), and Momentum (81) factor ranks across MoatMap’s 19,000+ stock universe.
Does Liquidia Corporation have an economic moat?
Liquidia Corporation (LQDA) has a Quality factor score of 63/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Liquidia Corporation a buy, hold, or sell?
MoatMap’s current signal for Liquidia Corporation (LQDA) is Buy, based on a StockRank of 69/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Liquidia Corporation in?
Liquidia Corporation (LQDA) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksLQDA deep dive reportAI ChampionsHow we score stocksSense-check another stock